| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5682921 | La Presse Médicale | 2017 | 9 Pages |
Abstract
Therapies targeting mutations in the MAPK pathway represent new therapeutic options that need to be appropriately evaluated pulmonary LCH.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Gwenaël Lorillon, Véronique Meignin, Abdellatif Tazi,